Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

CorMedix (CRMD) Raw Materials (2019 - 2025)

CorMedix (CRMD) has disclosed Raw Materials for 4 consecutive years, with $3.6 million as the latest value for Q4 2025.

Quarterly Raw Materials rose 227.18% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 227.18% year-over-year, with the annual reading at $3.6 million for FY2025, 227.18% up from the prior year.
Raw Materials hit $3.6 million in Q4 2025 for CorMedix, down from $7.0 million in the prior quarter.
In the past five years, Raw Materials ranged from a high of $7.0 million in Q3 2025 to a low of $603545.0 in Q3 2024.